🟢 Cerenome is trading 6.9% up as reason remains unclear

Cerenome is trading 6.9% higher at $1.70, with no clear catalyst identified.

• No October 7 company announcement was identified.
• An October 6 launch announcement covered two CNSide cerebrospinal-fluid molecular profiling tests, available to U.S. healthcare professionals beginning October 12; the release did not link them to the share-price move.
• Major U.S. indexes were lower. The supplied sector context showed healthcare higher, but did not establish it as the driver of Cerenome’s move.